Diabetes Research and Care Through the Ages.

Published on Oct 1, 2017in Diabetes Care16.019
· DOI :10.2337/DCI17-0042
Bernard Zinman42
Estimated H-index: 42
(Lunenfeld-Tanenbaum Research Institute),
Jay S. Skyler76
Estimated H-index: 76
(UM: University of Miami)
+ 1 AuthorsEle Ferrannini110
Estimated H-index: 110
(UniPi: University of Pisa)
Sources
Abstract
As has been well established, the Diabetes Care journal’s most visible signature event is the Diabetes Care Symposium held each year during the American Diabetes Association’s Scientific Sessions. Held this past year on 10 June 2017 in San Diego, California, at the 77th Scientific Sessions, this event has become one of the most attended sessions during the Scientific Sessions. Each year, in order to continue to have the symposium generate interest, we revise the format and content of this event. For this past year, our 6th annual symposium, I felt it was time to provide a comprehensive overview of our efforts in diabetes care to determine, first and foremost, how we arrived at our current state of management. I also felt the narrative needed to include the current status of management, especially with a focus toward cardiovascular disease, and finally, we wanted to ask what the future holds. Toward this goal, I asked four of the most noted experts in the world to provide their opinion on this topic. The symposium started with a very thoughtful presentation by Dr. Jay Skyler entitled “A Look Back as to How We Got Here.” That was followed by two lectures on current concepts by Dr. Bernard Zinman entitled “Current Treatment Paradigms Today—How Well Are We Doing?” and by Dr. Matthew Riddle entitled “Evolving Concepts and Future Directions for Cardiovascular Outcomes Trials.” The final lecture for the symposium was delivered by Dr. Ele Ferrannini and was entitled “What Does the Future Hold?” As always, a well-attended and well-received symposium is now the norm for our signature event and our efforts were rewarded by the enthusiasm of the attendees. This narrative summarizes the lectures held at the symposium. —William T. Cefalu Chief Scientific, Medical & Mission Officer, American Diabetes Association
📖 Papers frequently viewed together
20155.21Heart
References103
Newest
#1Edoardo Mannucci (UniFI: University of Florence)H-Index: 98
#2Ele FerranniniH-Index: 110
Last. Ele FerranniniH-Index: 14
view all 2 authors...
6 CitationsSource
#1Bruce NealH-Index: 116
#2Vlado PerkovicH-Index: 93
Last. David R. Matthews (University of Oxford)H-Index: 84
view all 10 authors...
BackgroundCanagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. MethodsThe CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin o...
3,149 CitationsSource
#1Thomas Nyström (KI: Karolinska Institutet)H-Index: 30
#2Johan Bodegard (AstraZeneca)H-Index: 24
Last. Jan W. Eriksson (Uppsala University)H-Index: 47
view all 6 authors...
Aims To investigate the association of novel oral glucose-lowering drugs (GLDs), compared with that of insulin, with risk of all-cause mortality, cardiovascular disease (CVD) and severe hypoglycaemia. Methods During 2013 to 2014 all patients with type 2 diabetes in Sweden identified as new users of novel oral GLDs, either dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT2) inhibitors (only dapagliflozin available in Sweden during the study period), with those init...
57 CitationsSource
#1Christian M. Cohrs (TUD: Dresden University of Technology)H-Index: 11
#2Chunguang Chen (TUD: Dresden University of Technology)H-Index: 6
Last. Stephan Speier (TUD: Dresden University of Technology)H-Index: 21
view all 15 authors...
Islet-cell hormone release is modulated by signals from endothelial and endocrine cells within the islet. However, models of intraislet vascularization and paracrine cell signaling are mostly based on the rodent pancreas. We assessed the architecture and endocrine cell interaction of the vascular network in unperturbed human islets in situ and their potential to re-establish their endogenous vascular network after transplantation in vivo. We prepared slices of fresh pancreas tissue obtained from...
40 CitationsSource
#1Ramesh Kandimalla (TTUHSC: Texas Tech University Health Sciences Center)H-Index: 28
#2Vani Thirumala (University of Texas at Austin)H-Index: 1
Last. P. Hemachandra Reddy (TTUHSC: Texas Tech University Health Sciences Center)H-Index: 72
view all 3 authors...
Abstract Recently researchers proposed the term ‘Type-3-Diabetes’ for Alzheimer's disease (ad) because of the shared molecular and cellular features among Type-1-Diabetes, Type-2-Diabetes and insulin resistance associated with memory deficits and cognitive decline in elderly individuals. Recent clinical and basic studies on patients with diabetes and AD revealed previously unreported cellular and pathological among diabetes, insulin resistance and AD. These studies are also strengthened by vario...
221 CitationsSource
Understanding how pancreatic β cells achieve and maintain functional identity as insulin-secreting cells is a major roadblock in our understanding of the aetiology of diabetes mellitus. Three new papers reveal the roles, in the adult β cell, of four transcription factors that are crucial for reprogramming a multipotent endocrine progenitor.
4 CitationsSource
Summary The bile acid receptor TGR5 (also known as GPBAR1) is a promising target for the development of pharmacological interventions in metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis. TGR5 is expressed in many metabolically active tissues, but complex enterohepatic bile acid cycling limits the exposure of some of these tissues to the receptor ligand. Profound interspecies differences in the biology of bile acids and their receptors in different cells a...
60 CitationsSource
#1Alan J. GarberH-Index: 57
Last. Guillermo E. UmpierrezH-Index: 6
view all 20 authors...
Abbreviations: A1C = hemoglobin A1C AACE = American Association of Clinical Endocrinologists ACCORD = Action to Control Cardiovascular Risk in Diabetes ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure ACEI = angiotensin-converting enzyme inhibitor ADVANCE = Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation AGI = alpha-glucosidase inhibitor apo B = apolipoprotein B ASCVD = atherosclerotic cardiovascular disease BAS = bile acid seq...
295 CitationsSource
#1Mark I. McCarthy (University of Oxford)H-Index: 200
The current focus on delivery of personalised (or precision) medicine reflects the expectation that developments in genomics, imaging and other domains will extend our diagnostic and prognostic capabilities, and enable more effective targeting of current and future preventative and therapeutic options. The clinical benefits of this approach are already being realised in rare diseases and cancer but the impact on management of complex diseases, such as type 2 diabetes, remains limited. This may r...
81 CitationsSource
#1Jay S. Skyler (UM: University of Miami)H-Index: 76
#2George L. Bakris (U of C: University of Chicago)H-Index: 135
Last. Robert E. Ratner (American Diabetes Association)H-Index: 61
view all 17 authors...
The American Diabetes Association, JDRF, the European Association for the Study of Diabetes, and the American Association of Clinical Endocrinologists convened a research symposium, “The Differentiation of Diabetes by Pathophysiology, Natural History and Prognosis” on 10–12 October 2015. International experts in genetics, immunology, metabolism, endocrinology, and systems biology discussed genetic and environmental determinants of type 1 and type 2 diabetes risk and progression, as well as compl...
232 CitationsSource
Cited By7
Newest
Source
#1Felipe Arroyave (Universidad de La Sabana)H-Index: 1
#2Diana Montaño (Universidad de La Sabana)
Last. Fernando Lizcano (Universidad de La Sabana)H-Index: 13
view all 3 authors...
Diabetes mellitus (DM) is one of the main causes of morbidity and mortality, with an increasing incidence worldwide. The impact of DM on public health in developing countries has triggered alarm due to the exaggerated costs of the treatment and monitoring of patients with this disease. Considerable efforts have been made to try to prevent the onset and reduce the complications of DM. However, because insulin-producing pancreatic β-cells progressively deteriorate, many people must receive insulin...
Source
#1Xavier CosH-Index: 12
#2Samuel Seidu (Leicester General Hospital)H-Index: 19
Last. Kamlesh Khunti (Leicester General Hospital)H-Index: 96
view all 9 authors...
Abstract Primary care physicians are uniquely placed to offer holistic, patient-centred care to patients with T2DM. While the recent FDA-mandated cardiovascular outcome trials offer a wealth of data to inform treatment discussions, they have also contributed to increasing complexity in treatment decisions, and in the guidelines that seek to assist in making these decisions. To assist physicians in avoiding treatment inertia, Primary Care Diabetes Europe has formulated a position statement that s...
2 CitationsSource
Source
The first diabetes clinics were established in North America and Europe following the discovery of insulin with the main objective of teaching patients the technique and principles of its use. Patients with diabetes were mostly treated in hospitals by specialists, but the increasing prevalence of type 2 diabetes made this unpractical. Failure of overwhelmed hospital clinics prompted the creation of “small clinics of general practice” where general physicians were organized to assist small groups...
1 CitationsSource
At the Scientific Sessions of the American Diabetes Association in 1992, Professor Gian Franco Bottazzo delivered the Banting Lecture, in which he announced that diabetes was “a new disease,” based on criteria originally described by Mirko D. Grmek in his classical book about the history of AIDS:
1 CitationsSource
#1Harpreet S. Bajaj (MSH: Mount Sinai Hospital, Toronto)H-Index: 11
#2Bernard Zinman (U of T: University of Toronto)H-Index: 103
Recent trials in Type 2 diabetes (T2D) have shown cardiovascular benefits with specific GLP-1 receptor agonists and SGLT2 inhibitors. We discuss the landscape of outcome trials in T2D from a pathophysiology viewpoint, review current knowledge gaps in underlying mechanisms, propose a caloric fuel routing hypothesis, and highlight areas of future research.
3 CitationsSource